October 10, 2020

10 Oct 20 | All | Celltrion | Celltrion presents positive interim results from Ph I trials of CT-P13 of subcutaneous Remsima® (biosimilar infliximab) in IBD at the UEG Week Virtual 2020. The results indicated that subcutaneous infliximab may be associated with better c...

Please reload

Biosimilars bulletin 

October 4, 2020

Please reload

Search by tags